Vivold Consulting

How a Gemma model helped discover a new potential cancer therapy pathway

Key Insights

DeepMind introduces a 27-billion parameter foundation model for single-cell analysis, built on the Gemma family of open models. This model has identified a new pathway that could lead to innovative cancer treatments.

Stay Updated

Get the latest insights delivered to your inbox

A Game-Changer in Cancer Research?

DeepMind's latest AI model has uncovered a previously unknown pathway that may be instrumental in developing new cancer therapies. This breakthrough underscores the potential of AI in accelerating medical discoveries.

Key Takeaways

- Massive Scale: The 27-billion parameter model offers unprecedented analytical capabilities.
- Single-Cell Precision: Focuses on individual cell analysis, providing detailed insights into cellular behaviors.
- Open Model Framework: Built on the Gemma family, promoting transparency and collaboration in research.

Implications for Healthcare

This development could expedite the identification of novel treatment pathways, potentially leading to more effective and personalized cancer therapies. It also highlights the growing role of AI in transforming biomedical research.

Related Articles

An AWS knowledge-graph deployment turned 6-month research cycles into 3 weeks - and the blueprint transfers far beyond pharma

An AWS GraphRAG deployment in pharmaceutical research cut R&D cycles by 87% - initial discovery that took six months now closes in three weeks - by fusing siloed internal databases and public literature into one queryable knowledge graph on Amazon Neptune Analytics and Bedrock (running Claude). Every answer comes with verifiable citations and a mapped reasoning path, which is exactly what regulated industries need for compliance. The architecture is modular and, crucially, transferable: any enterprise drowning in fragmented legacy data can copy this pattern.

SpaceX, Anthropic, and OpenAI listings will out-value every US VC-backed exit since 2000 - reshaping vendor economics for everyone

The new NVCA-Pitchbook Venture Monitor dropped a stunning claim: the pending OpenAI and Anthropic IPOs, together with SpaceX's listing, will generate more value than every US VC-backed exit since 2000 combined. SpaceX is already public at $1.77 trillion, and with both AI labs pushing toward trillion-dollar debuts, the trio should land north of $4 trillion - against roughly $70 billion in total US IPO proceeds last year. For anyone buying AI services, the labs' shift to public-market scrutiny will reshape pricing, transparency, and vendor stability.

A 14-person open-source team just became the default way 8.9M developers run local AI - and a lever for slashing inference bills

Ollama, the open-source tool that lets developers run open-weight AI models on their own machines in minutes, raised a $65M Series B led by Theory Ventures ($88M total), revealing it now serves 8.9 million developers monthly and sits inside 85% of the Fortune 500 - with just 14 employees. Founders Jeff Morgan and Michael Chiang previously built Docker Desktop, and they're repeating the play: abstract away the hardware pain, then monetise a cloud tier priced on GPU time rather than tokens. The backdrop is the industry's loudest cost debate: every company with heavy inference bills is under existential pressure to shift routine workloads to open models.